237 related articles for article (PubMed ID: 29566742)
1. Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis.
Cappelli LC; Konig MF; Gelber AC; Bingham CO; Darrah E
Arthritis Res Ther; 2018 Mar; 20(1):59. PubMed ID: 29566742
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.
Darrah E; Giles JT; Davis RL; Naik P; Wang H; Konig MF; Cappelli LC; Bingham CO; Danoff SK; Andrade F
Front Immunol; 2018; 9():2696. PubMed ID: 30515171
[No Abstract] [Full Text] [Related]
3. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
[TBL] [Abstract][Full Text] [Related]
4. Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans.
Navarro-Millán I; Darrah E; Westfall AO; Mikuls TR; Reynolds RJ; Danila MI; Curtis JR; ; Rosen A; Bridges SL
Arthritis Res Ther; 2016 Oct; 18(1):241. PubMed ID: 27770831
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.
Ferucci ED; Darrah E; Smolik I; Choromanski TL; Robinson DB; Newkirk MM; Fritzler MJ; Rosen A; El-Gabalawy HS
J Rheumatol; 2013 Sep; 40(9):1523-8. PubMed ID: 23908443
[TBL] [Abstract][Full Text] [Related]
6. Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
Shi J; Darrah E; Sims GP; Mustelin T; Sampson K; Konig MF; Bingham CO; Rosen A; Andrade F
Ann Rheum Dis; 2018 Jan; 77(1):141-148. PubMed ID: 29070531
[TBL] [Abstract][Full Text] [Related]
7. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease.
Giles JT; Darrah E; Danoff S; Johnson C; Andrade F; Rosen A; Bathon JM
PLoS One; 2014; 9(6):e98794. PubMed ID: 24901704
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
Umeda N; Matsumoto I; Kawaguchi H; Kurashima Y; Kondo Y; Tsuboi H; Ogishima H; Suzuki T; Kagami Y; Sakyu T; Ishigami A; Maruyama N; Sumida T
Clin Rheumatol; 2016 May; 35(5):1181-8. PubMed ID: 26415740
[TBL] [Abstract][Full Text] [Related]
9. Serum antibodies to peptidylarginine deiminase-4 in rheumatoid arthritis associated-interstitial lung disease are associated with decreased lung fibrosis and improved survival.
Wilson TM; Solomon JJ; Humphries SM; Swigris JJ; Ahmed F; Wang H; Darrah E; Demoruelle MK
Am J Med Sci; 2023 Jun; 365(6):480-487. PubMed ID: 36918112
[TBL] [Abstract][Full Text] [Related]
10. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model.
Auger I; Balandraud N; Massy E; Hemon MF; Peen E; Arnoux F; Mariot C; Martin M; Lafforgue P; Busnel JM; Roudier J
Arthritis Rheumatol; 2020 Jun; 72(6):903-911. PubMed ID: 31820586
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
12. Anti-protein arginine deiminase antibodies are distinctly associated with joint and lung involvement in rheumatoid arthritis.
Palterer B; Vitiello G; Del Carria M; D'Onofrio B; Martinez-Prat L; Mahler M; Cammelli D; Parronchi P
Rheumatology (Oxford); 2023 Jul; 62(7):2410-2417. PubMed ID: 36440916
[TBL] [Abstract][Full Text] [Related]
13. Heavy Chain Constant Region Usage in Antibodies to Peptidylarginine Deiminase 4 as a Marker of Disease Subsets in Rheumatoid Arthritis.
Gómez-Bañuelos E; Shi J; Wang H; Danila MI; Bridges SL; Giles JT; Sims GP; Andrade F; Darrah E
Arthritis Rheumatol; 2022 Nov; 74(11):1746-1754. PubMed ID: 35675168
[TBL] [Abstract][Full Text] [Related]
14. Anti-peptidyl-arginine deaminase 3 (PAD3) antibodies as a promising marker to measure joint damage in patients with rheumatoid arthritis.
Seaman A; Darrah E; Infantino M; Meacci F; Manfredi M; Benucci M; Mahler M
Autoimmun Rev; 2016 Jul; 15(7):776-80. PubMed ID: 26997641
[TBL] [Abstract][Full Text] [Related]
15. Association of Baseline Peptidylarginine Deiminase 4 Autoantibodies With Favorable Response to Treatment Escalation in Rheumatoid Arthritis.
Darrah E; Yu F; Cappelli LC; Rosen A; O'Dell JR; Mikuls TR
Arthritis Rheumatol; 2019 May; 71(5):696-702. PubMed ID: 30507066
[TBL] [Abstract][Full Text] [Related]
16. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic values, association with disease activity and possible risk factors of anti-PAD4 in rheumatoid arthritis: a meta-analysis.
Zhang G; Xu J; Du D; Liu Y; Dai L; Zhao Y
Rheumatology (Oxford); 2024 Apr; 63(4):914-924. PubMed ID: 37824204
[TBL] [Abstract][Full Text] [Related]
18. Expression of anti-Porphyromonas gingivalis peptidylarginine deiminase immunoglobulin G and peptidylarginine deiminase-4 in patients with rheumatoid arthritis and periodontitis.
Shimada A; Kobayashi T; Ito S; Okada M; Murasawa A; Nakazono K; Yoshie H
J Periodontal Res; 2016 Feb; 51(1):103-11. PubMed ID: 26094771
[TBL] [Abstract][Full Text] [Related]
19. Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis.
Poór G; Nagy ZB; Schmidt Z; Brózik M; Merétey K; Gergely P
Ann N Y Acad Sci; 2007 Sep; 1110():23-32. PubMed ID: 17911417
[TBL] [Abstract][Full Text] [Related]
20. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies.
Jiang X; Trouw LA; van Wesemael TJ; Shi J; Bengtsson C; Källberg H; Malmström V; Israelsson L; Hreggvidsdottir H; Verduijn W; Klareskog L; Alfredsson L; Huizinga TW; Toes RE; Lundberg K; van der Woude D
Ann Rheum Dis; 2014 Oct; 73(10):1761-8. PubMed ID: 24812286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
